SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ANTI PD-L1 "BENMELSTOBART (TQB2450 INJECTION)" INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURES

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that "Benmelstobart (TQB2450 Injection)" developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Company, has been included in the priority review and approval procedures by the Center for Drug Evaluation (the "**CDE**") of the National Medical Products Administration of the PRC for the treatment of recurrent or metastatic endometrial cancer in combination with Anlotinib Hydrochloride Capsules.

Benmelstobart is a novel fully humanized anti PD-L1 monoclonal antibody with a new sequence self-developed by the Group. In April 2022, Benmelstobart in combination with anlotinib was included in the breakthrough therapy category by the CDE for the treatment of recurrent or metastatic endometrial cancer. In January 2023, the new drug application for Benmelstobart was formally accepted by the CDE for first-line treatment of small cell lung cancer in combination with anlotinib.

Endometrial cancer ranks second among malignant tumors of the female reproductive system in China, and first in developed countries[1]. With the increasing prevalence of high-fat and high-calorie dietary patterns and the gradual spread of unhealthy lifestyles, the incidence of endometrial cancer continues to rise, especially among younger women in China[1]. In 2016, the number of new cases of endometrial cancer reached 71,000 in China, with an incidence rate of 10.54 per 100,000 people[2]. Currently, platinum-based chemotherapy is the first-line therapy for endometrial cancer in China. However, for patients with progress after first-line treatment, there is no standard clinical treatment protocol; patients have limited clinical treatment options and poor prognosis; thus, there is urgent need for effective treatment modalities.

This inclusion in the priority review and approval procedures is expected to expedite the review for market launch of Benmelstobart, addressing unmet clinical needs and benefiting domestic patients as soon as possible. At the same time, it also signifies successful expansion into another important field for Benmelstobart following its success in the field of small cell lung cancer. Clinical phase III trials of Benmelstobart in combination with anlotinib are underway, including those for the treatment of first-line renal cancer, first-line non-small cell lung cancer, and maintenance therapy after non-small cell lung cancer radiotherapy and chemotherapy. The Group will continue to promote the development of Benmelstobart, bringing new treatment options to more patients.

Notes:

1 Chinese Expert Consensus Compilation Group for Multiple Disciplinary Treatment in Endometrial Cancer Desiring Fertility Preserving Treatment Writers, Chinese expert consensus on multiple disciplinary treatment in endometrial cancer desiring fertility preserving treatment [J]. Journal of Reproduction and Contraception, 2023, 43(4): 346-356.

2 Rongshou Zheng et al. Cancer incidence and mortality in China, 2016, Journal of the National Cancer Center, 2022, 2(1): 1-9.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 February 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.